potential biomarkers of pembrolizumab response after hidac in r/r aml
Published 5 years ago • 158 plays • Length 1:58Download video MP4
Download video MP3
Similar videos
-
1:12
using biomarkers and genomics to inform treatment strategy in all
-
5:13
phase ii trial of pembrolizumab prior to allo-sct in aml
-
2:01
predict response to immune checkpoint inhibition in acute myeloid leukemia (aml) using biomarkers
-
1:31
pembrolizumab plus avd in chl: long-term follow-up of a phase ii study
-
3:37
biomarker analysis of luspatercept versus epoetin alfa in lr-mds in the phase iii commands study
-
7:23
success principles of cancer immunotherapy
-
3:19
what is immuno-oncology?
-
21:24
cell surface markers: cd3, cd4, cd8, cd19, cd28, cd16, cd56
-
2:25
biomarkers of progression and risk stratification in asymptomatic waldenström's macroglobulinemia
-
1:52
evaluating the efficacy of obinutuzumab, ibrutinib, and venetoclax in richter's transformation
-
1:38
lba: komet-001 - ziftomenib monotherapy in r/r npm1-mutated aml
-
1:19
the potential of caplacizumab in the treatment of attp
-
1:35
phase i/ii bruin update: efficacy of pirtobrutinib in r/r waldenström's macroglobulinemia
-
1:33:24
new horizons for biomarker technologies
-
1:05
the future of immuno-oncology
-
4:42
legato demo: hipermab for evaluating the potential of biomarker pilot studies
-
37:31
update on immuno-oncology biomarkers
-
6:47
new biomarkers for response to immunotherapy
-
1:14
predicting patient response to btk inhibitors using novel approaches
-
4:48
an insight into the management of cytopenias in mf
-
15:00
biomarkers and lipidology
-
1:00
biomarkers oef